Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Main chromosomal aberrations detected in BRCA1 -mutated TNBC

From: Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer

   BRCA1-mutated BRCA1-non-mutated
Chromosomes Cytobandes Gains, % Losses, % Gains, % Losses, %
chr5 q14.3 - q21.2 0.36 43.48 0.00 15.08
chr5 q23.1 0.00 39.13 0.00 14.29
chr7 p22.1 26.09 13.04 4.76 11.91
chr8 q24.3 82.61 4.35 57.14 9.52
chr11 p15.5 26.09 8.70 4.76 47.62
chr11 q24.3 4.35 26.09 19.05 4.76
chr12 p12.1 8.70 34.78 47.62 14.29
chr12 q21.33 0.00 39.13 4.76 9.52
chr15 q22.31 26.09 13.04 4.76 14.29
chr15 q24.1 - q24.2 23.92 16.67 2.38 33.33
chr16 q24.3 32.29 13.04 9.52 41.50
chr17 q24.1 39.13 4.35 14.29 4.76
chr17 q24.3 35.87 0.00 9.52 4.76
chr17 q25.1 - q25.3 58.95 3.59 25.12 21.63
chr18 q12.1 10.87 28.26 15.48 4.76
chr18 q12.3 0.00 42.03 0.00 14.29
chr19 q13.2 21.74 4.35 0.00 42.86
chr19 q13.33 21.74 8.70 0.00 42.86
chr19 q13.42 26.09 17.39 4.76 38.10
chr22 q12.3 49.28 11.59 11.91 30.16
chr22 q13.1 50.79 11.07 19.70 33.33
  1. Significant aberrations (P-value ≤0.05) with a variation of gains or losses between BRCA1-mutated and non-mutated triple-negative breast cancer (TBNC) of at least 20% are indicated.